Abstract:Due to the absence of accurate tools for early detection and successful treatment, lung adenocarcinoma (LUAD) is one of the most aggressive tumors with high morbidity and mortality globally. It is absolutely necessary to investigate the process behind its development and search for new biomarkers that could aid in the early detection of LUAD. There is a correlation between the immune microenvironment of the tumor and the prognosis of lung cancer as well as the efficacy of immunotherapy. Long noncoding RNAs (lncRNAs) have been identified as potential prognostic biomarkers linked to immunological activities. In this study, we identified 1 downregulated lncRNA and 76 upregulated lncRNAs in LUAD samples from TCGA datasets. Among the 77 dysregulated lncRNAs, our attention focused on lncRNA LINC01833 (LINC01833). When compared with nontumor specimens, the level of expression of LINC01833 was shown to be significantly elevated in LUAD samples. In addition, the data of the ROC study revealed that LUAD patients with high LINC01833 expression had an AUC value of 0.840 (95% confidence interval: 0.804 to 0.876). There was a correlation between high LINC01833 expression and an advanced clinical stage. Patients who had a high expression of LINC01833 were shown to have a lower overall survival rate p < 0.001 and a lower disease-specific survival rate (p = 0.004) in comparison to patients who were in the low LINC01833 group, according to the data on survival. In addition, the results of the multivariate analysis revealed that high LINC01833 expression was an independent predictor of poor survival in LUAD. Moreover, the immune analysis revealed that we found that the expression of LINC01833 was positively associated with Th2 cells, aDC, and Tgd, while negatively associated with Mast cells, Tcm, Eosinophils, iDC, DC, Tem, Th17 cells, and pDC. Overall, our data point to the possibility that the unique lncRNA LINC01833 might be employed as a diagnostic and prognostic marker, and as a result, it has a significant impact on clinical practice.

Additional File 3: Table S5. of Differential Expression Analysis at the Individual Level Reveals a Lncrna Prognostic Signature for Lung Adenocarcinoma

Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Differential Expression Analysis at the Individual Level Reveals a Lncrna Prognostic Signature for Lung Adenocarcinoma

Additional File 3 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

Additional File 6 of Comparative Profiling of Single-Cell Transcriptome Reveals Heterogeneity of Tumor Microenvironment Between Solid and Acinar Lung Adenocarcinoma

Additional File 7 of Plasma Trna-Derived Small RNAs Signature As a Predictive and Prognostic Biomarker in Lung Adenocarcinoma

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

Microarray Profiling of Differentially Expressed Lncrnas and Mrnas in Lung Adenocarcinomas and Bioinformatics Analysis

Additional File 5 of Comparative Profiling of Single-Cell Transcriptome Reveals Heterogeneity of Tumor Microenvironment Between Solid and Acinar Lung Adenocarcinoma

Genome-wide Analyses of Long Noncoding RNA Expression Profiles in Lung Adenocarcinoma

LncRNA Expression Signature in Prediction of the Prognosis of Lung Adenocarcinoma.

Additional File 3: Table S2. of A Long Non-Coding RNA Signature to Improve Prognosis Prediction of Gastric Cancer

Expression profiles of long noncoding RNAs in lung adenocarcinoma.

Additional File 1: Table S1. of Genome-wide Analyses of Long Noncoding RNA Expression Profiles Correlated with Radioresistance in Nasopharyngeal Carcinoma Via Next-Generation Deep Sequencing

A Group of Long Noncoding RNAs Identified by Data Mining Can Predict the Prognosis of Lung Adenocarcinoma

Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma

Additional File 6: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Identification of Three Lncrnas As Potential Predictive Biomarkers of Lung Adenocarcinoma

Development of a Novel Prognostic Signature of Long Non-Coding RNAs in Lung Adenocarcinoma

LncRNA LINC01833 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Patients with Lung Adenocarcinoma by Integrated Bioinformatics Analysis

Microarray Expression Profile of Long Non-Coding RNAs in Human Lung Adenocarcinoma.